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Type I interferons represent the first line of defense
against pathogens. This family of cytokines activates the
expression of antiviral proteins, such as the protein
kinase R (PKR), an inhibitor of viral mRNA translation,
and the double-stranded RNA adenosine deaminase
ADAR1. ADAR1 has the ability to convert adenosine
(A) into guanosine (G), thereby introducing mutations
in the viral genome during its replication. A to G editing
was previously reported in cells expressing HTLV-2 or
STLV-3 viruses but not investigating in HTLV-1 expres-
sing cells (Ko et al. J. Gen Virol. 2013). Consequently
we investigated whether ADAR1 expression was asso-
ciated or not with an antiviral effect in the course of
HTLV-1 and HTLV-2 infections. We first show that
ADAR1 expression is increased in ATL patient periph-
eral blood mononuclear cells, in HTLV-1 and HTLV-2
transformed cell lines as well as in activated primary
peripheral blood lymphocytes. Strikingly, in cells trans-
fected with HTLV-1 and HTLV-2 molecular clones,
ADAR1 over-expression enhances viral replication and
viral egress through PKR functional inhibition, as demon-
strated by western-blot analyses, luciferase assays, ELISA
and infection experiments. We also demonstrate that this
effect is independent of ADAR catalytic activity. In
addition, ADAR1 expression enhances the susceptibility
of a non-infected T cell line to HTLV-1 and HTLV-2
infection. Altogether, our results demonstrate that an
interferon-induced protein exerts a proviral role in the
context of HTLV infection by enhancing cells susceptibil-
ity to infection and increasing viral replication.
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